Cited by 557CRISPR and Genetic EngineeringAcute Myeloid Leukemia ResearchChromatin Remodeling and Cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing

Open access

Heckl, Dirk, Kowalczyk, Monika S, Yudovich, David, Belizaire, Roger, Puram, Rishi V, McConkey, Marie E, Thielke, Anne, Aster, Jon C, Regev, Aviv, Ebert, Benjamin L·2014·Nature Biotechnology

DOI 10.1038/nbt.2951PMC PMC4160386

Open this paper in CoChat — free account

Abstract

Genome sequencing studies have shown that human malignancies often bear mutations in four or more driver genes, but it is difficult to recapitulate this degree of genetic complexity in mouse models using conventional breeding. Here we use the CRISPR-Cas9 system of genome editing to overcome this limitation. By delivering combinations of small guide RNAs (sgRNAs) and Cas9 with a lentiviral vector, we modified up to five genes in a single mouse hematopoietic stem cell (HSC), leading to clonal outgrowth and myeloid malignancy. We thereby generated models of acute myeloid leukemia (AML) with cooperating mutations in genes encoding epigenetic modifiers, transcription factors and mediators of cytokine signaling, recapitulating the combinations of mutations observed in patients. Our results suggest that lentivirus-delivered sgRNA:Cas9 genome editing should be useful to engineer a broad array of in vivo cancer models that better reflect the complexity of human disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nbt.2951

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citation
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Efficient genome editing in zebrafish using a CRISPR-Cas system
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856

Show all 27 references

Sorted by citations

Items 201–300 of 557

CRISPR ‐Cas9 technology and its application in haematological disorders
Zhang, H., & McCarty, N. (2016) · British Journal of Haematology · doi:10.1111/bjh.14297 · Cited by 37
Improving the knock-in efficiency of the MOF-encapsulated CRISPR/Cas9 system through controllable embedding structures
Liu, C., Xu, X., Koivisto, O., Zhou, W., Jacquemet, G., Rosenholm, J. M., & Zhang, H. (2021) · Nanoscale · doi:10.1039/d1nr02872c · Cited by 38
CD47 cross-dressing by extracellular vesicles expressing CD47 inhibits phagocytosis without transmitting cell death signals
Li, Y., Wu, Y. P., Federzoni, E. A., Wang, X., Dharmawan, A., Hu, X., Wang, H., Hawley, R. J., Stevens, S. G., Sykes, M., et al. (2022) · eLife · doi:10.7554/elife.73677 · Cited by 36
Genome-wide identification and characterization of Notch transcription complex–binding sequence-paired sites in leukemia cells
Severson, E. A., Arnett, K. L., Wang, H., Zang, C., Taing, L., Liu, H., Pear, W. S., Liu, X. S., Blacklow, S. C., & Aster, J. C. (2017) · Science Signaling · doi:10.1126/scisignal.aag1598 · Cited by 36
Self-citation
CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice
Li, S., Holguin, L., & Burnett, J. C. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.012 · Cited by 38
Unlocking Genome Editing: Advances and Obstacles in CRISPR/Cas Delivery Technologies
Kaupbayeva, B., Tsoy, A., Safarova, Y., Nurmagambetova, A., Murata, H., Matyjaszewski, K. A., & Askarova, S. (2024) · Journal of Functional Biomaterials · doi:10.3390/jfb15110324 · Cited by 40
A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way?
Taylor, J., & Woodcock, S. A. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115590069 · Cited by 35
Neuron-Specific Gene 2 (NSG2) Encodes an AMPA Receptor Interacting Protein That Modulates Excitatory Neurotransmission
Chander, P. N., Kennedy, M. J., Winckler, B., & Weick, J. P. (2019) · eNeuro · doi:10.1523/eneuro.0292-18.2018 · Cited by 34
Activation of CpG-Rich Promoters Mediated by MLL Drives MOZ-Rearranged Leukemia.
Miyamoto, R., Okuda, H., Kanai, A., Takahashi, S., Kawamura, T., Matsui, H., Kitamura, T., Kitabayashi, I., Inaba, T., & Yokoyama, A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108200 · Cited by 34
Strategies for High-Efficiency Mutation Using the CRISPR/Cas System
Feng, S., Wang, Z., Li, A., Xie, X., Liu, J., Li, S., Li, Y., Wang, B., Hu, L., Yang, L., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.803252 · Cited by 40
IMPDH inhibition activates TLR‐VCAM1 pathway and suppresses the development of MLL‐fusion leukemia
Liu, X., Sato, N., Yabushita, T., Li, J., Jia, Y., Tamura, M., Asada, S., Fujino, T., Fukushima, T., Yonezawa, T., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115631 · Cited by 34
Neuropilin-1 is essential for vascular endothelial growth factor A–mediated increase of sensory neuron activity and development of pain-like behaviors
Gómez, K., Duran, P., Tonello, R., Allen, H. N., Boinon, L., Calderón‐Rivera, A., Loya‐López, S., Nelson, T. S., Ran, D., Moutal, A., et al. (2023) · Pain · doi:10.1097/j.pain.0000000000002970 · Cited by 33
Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma
Liu, T., Shen, J. K., Li, Z., Choy, E., Hornicek, F. J., & Duan, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.030 · Cited by 30
SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression
Lin, C.-H., Wong, S. H. K., Kurzer, J. H., Schneidawind, C., Wei, M. C., Duque‐Afonso, J., Jeong, J., Feng, X., & Cleary, M. L. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.124 · Cited by 34
Amyloid Precursor Protein (APP) Controls the Expression of the Transcriptional Activator Neuronal PAS Domain Protein 4 (NPAS4) and Synaptic GABA Release
Opsomer, R., Contino, S., Perrin, F., Gualdani, R., Tasiaux, B., Doyen, P. J., Vergouts, M., Vrancx, C., Doshina, A., Pierrot, N., et al. (2020) · eNeuro · doi:10.1523/eneuro.0322-19.2020 · Cited by 38
Green Light Antinociceptive and Reversal of Thermal and Mechanical Hypersensitivity Effects Rely on Endogenous Opioid System Stimulation
Martin, L. F., Moutal, A., Cheng, K., Washington, S. M., Calligaro, H., Goel, V., Kranz, T., Largent‐Milnes, T. M., Khanna, R., Patwardhan, A. M., et al. (2021) · Journal of Pain · doi:10.1016/j.jpain.2021.05.006 · Cited by 34
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
Patel, A. J., Warda, S., Mååg, J. L. V., Misra, R., Miranda-Román, M. A., Pachai, M. R., Lee, C. J., Li, D., Wang, N., Bayshtok, G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1671 · Cited by 36
CRISPR-Cas9: A Revolutionary Tool for Cancer Modelling
Torres-Ruiz, R., & Rodríguez, S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922151 · Cited by 37
A genome editing primer for the hematologist
Hoban, M. D., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2016-01-678151 · Cited by 32
Engineering CRISPR mouse models of cancer
Weber, J., & Rad, R. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.04.001 · Cited by 33
A non-inheritable maternal Cas9-based multiple-gene editing system in mice
Sakurai, T., Kamiyoshi, A., Kawate, H., Mori, C., Watanabe, S., Tanaka, M., Uetake, R., Sato, M., & Shindo, T. (2016) · Scientific Reports · doi:10.1038/srep20011 · Cited by 32
High throughput single-cell detection of multiplex CRISPR-edited gene modifications
ten Hacken, E., Clement, K., Li, S., Hernández‐Sánchez, M., Redd, R. A., Wang, S., Ruff, D., Gruber, M., Baranowski, K., Jacob, J. P., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02174-1 · Cited by 32
Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells
Rimando, J. C., Chendamarai, E., Rettig, M. P., Jayasinghe, R. G., Christopher, M. J., Ritchey, J., Christ, S., Kim, M. Y., Bonvini, E., & DiPersio, J. F. (2022) · Blood · doi:10.1182/blood.2022017795 · Cited by 32
Clonal hematopoiesis-related mutant ASXL1 promotes atherosclerosis in mice via dysregulated innate immunity
Sato, N., Goyama, S., Chang, Y., Miyawaki, M., Fujino, T., Koide, S., Denda, T., Liu, X., Ueda, K., Yamamoto, K., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00579-w · Cited by 38
CRISPR/Cas9 Immunoengineering of Hoxb8-Immortalized Progenitor Cells for Revealing CCR7-Mediated Dendritic Cell Signaling and Migration Mechanisms in vivo
Hammerschmidt, S. I., Werth, K., Rothe, M., Galla, M., Permanyer, M., Patzer, G. E., Bubke, A., Frenk, D. N., Selich, A., Lange, L., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01949 · Cited by 33
An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue
Jin, J., Xu, Y., Huo, L., Ma, L., Scott, A. W., Pizzi, M. P., Li, Y., Wang, Y., Yao, X., Song, S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228910 · Cited by 31
CRISPR, un système qui permet de corriger ou de modifier l’expression de gènes responsables de maladies héréditaires
Tremblay, J. P. (2015) · médecine/sciences · doi:10.1051/medsci/20153111016 · Cited by 39
Mapping DNA interaction landscapes in psoriasis susceptibility loci highlights KLF4 as a target gene in 9q31
Ray-Jones, H., Duffus, K., McGovern, A., Martin, P., Shi, C., Hankinson, J., Gough, O., Yarwood, A., Morris, A. P., Adamson, A., et al. (2020) · BMC Biology · doi:10.1186/s12915-020-00779-3 · Cited by 31
Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy
Abaza, T., Mohamed, E., & Zaky, M. Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02939-3 · Cited by 35
Genetically engineered mouse models for studying radiation biology
Castle, K. D., Chen, M., Wisdom, A. J., & Kirsch, D. G. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.06.19 · Cited by 32
CRMP2 is necessary for Neurofibromatosis type 1 related pain
Moutal, A., Cai, S., Luo, S., Voisin, R., & Khanna, R. (2017) · Channels · doi:10.1080/19336950.2017.1370524 · Cited by 30
CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Akram, F., Haq, I. U., Ahmed, Z., Khan, H. A., & Ali, M. S. (2020) · Protein and Peptide Letters · doi:10.2174/0929866527666200407112432 · Cited by 33
A bipartite element with allele-specific functions safeguards DNA methylation imprints at the Dlk1-Dio3 locus
Aronson, B. E., Scourzic, L., Shah, V., Swanzey, E., Kloetgen, A., Polyzos, A., Sinha, A., Azziz, A., Caspi, I., Li, J., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.10.004 · Cited by 34
Medical applications of clustered regularly interspaced short palindromic repeats (CRISPR/Cas) tool: A comprehensive overview
Araldi, R. P., Khalil, C., Grignet, P. H., Teixeira, M. R., de Melo, T. C., Módolo, D. G., Fernandes, L. G. V., Ruiz, J. L. M., & de Souza, E. B. (2020) · Gene · doi:10.1016/j.gene.2020.144636 · Cited by 33
Harnessing the evolving CRISPR/Cas9 for precision oncology
Li, T., Li, S., Kang, Y., Zhou, J., & Yi, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05570-4 · Cited by 35
Overcoming the Delivery Challenges in CRISPR/Cas9 Gene Editing for Effective Cancer Treatment: A Review of Delivery Systems
Tang, S., Chen, X., Tong, X., & Zhu, L. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.112724 · Cited by 31
Advancements in CRISPR/Cas9 technology—Focusing on cancer therapeutics and beyond
Mirza, Z., & Karim, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.026 · Cited by 29
MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome
Qiu, Z., Lin, A., Jiang, S., Elkashef, S. M., Myers, J., Srikantan, S., Sasi, B. K., Cao, J. Z., Godley, L. A., Rakheja, D., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.02.002 · Cited by 31
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
ten Hacken, E., Sewastianik, T., Yin, S., Hoffmann, G. B., Gruber, M., Clement, K., Penter, L., Redd, R. A., Ruthen, N. G., Hergalant, S., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0082 · Cited by 29
Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma
Tomska, K., Kurilov, R., Lee, K.-S., Hüllein, J., Lukas, M., Sellner, L., Walther, T., Wagner, L., Oleś, M., Brors, B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30509-3 · Cited by 28
Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies
Hwang, J., & Yokota, T. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.5 · Cited by 29
Murine models of clonal haematopoiesis to assess mechanisms of cardiovascular disease
Wang, Y., Sano, S., Ogawa, H., Horitani, K., Evans, M. A., Yura, Y., Miura‐Yura, E., Doviak, H., & Walsh, K. X. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab215 · Cited by 26
Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions
Weller, R., Hueging, K., Brown, R. J. P., Tödt, D., Joecks, S., Vondran, F. W. R., & Pietschmann, T. (2017) · Journal of Virology · doi:10.1128/jvi.00422-17 · Cited by 27
Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
Meyer, T., Jahn, N., Lindner, S., Röhner, L., Dolnik, A., Weber, D., Scheffold, A., Köpff, S., Paschka, P., Gaidzik, V. I., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0578-6 · Cited by 26
Self-citation
Distinct but interchangeable subpopulations of colorectal cancer cells with different growth fates and drug sensitivity
Coppo, R., Kondo, J., Iida, K., Okada, M., Onuma, K., Tanaka, Y., Kamada, M., Ohue, M., Kawada, K., Obama, K., et al. (2023) · iScience · doi:10.1016/j.isci.2023.105962 · Cited by 27
An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries
Adams, F. F., Heckl, D., Hoffmann, T., Talbot, S. R., Kloos, A., Thol, F. R., Heuser, M., Zuber, J. A., Schambach, A., & Schwarzer, A. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.05.032 · Cited by 25
Self-citation
Technical considerations for the use of CRISPR/Cas9 in hematology research
Gundry, M. C., Dever, D. P., Yudovich, D., Bauer, D. E., Haas, S., Wilkinson, A. C., & Singbrant, S. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.07.006 · Cited by 26
Self-citation
Therapeutic genome engineering via CRISPR ‐Cas systems
Moreno, A. M., & Mali, P. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1380 · Cited by 25
Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells
Yudovich, D., Bäckström, A., Schmiderer, L., Žemaitis, K., Subramaniam, A., & Larsson, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-79724-x · Cited by 26
Self-citation
HOXA9 promotes MYC-mediated leukemogenesis by maintaining gene expression for multiple anti-apoptotic pathways
Miyamoto, R., Kanai, A., Okuda, H., Komata, Y., Takahashi, S., Matsui, H., Inaba, T., & Yokoyama, A. (2021) · eLife · doi:10.7554/elife.64148 · Cited by 26
HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis
Takahashi, S., Kanai, A., Okuda, H., Miyamoto, R., Komata, Y., Kawamura, T., Matsui, H., Inaba, T., Takaori‐Kondo, A., & Yokoyama, A. (2021) · eLife · doi:10.7554/elife.65872 · Cited by 26
Viral Vectors, Exosomes, and Vexosomes: Potential armamentarium for delivering CRISPR/Cas to cancer cells
Farzanehpour, M., Miri, A., Alvanegh, A. G., & Gouvarchinghaleh, H. E. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115555 · Cited by 27
Nanoblades allow high-level genome editing in murine and human organoids
Tiroille, V., Krug, A., Bokobza, E., Kahi, M., Bulcaen, M., Ensinck, M. M., Geurts, M. H., Hendriks, D., Vermeulen, F., Larbret, F., et al. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2023.06.004 · Cited by 25
Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer
Godbole, N., Quinn, A., Carrión, F., Pelosi, E., & Salomón, C. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.10.002 · Cited by 25
Genome-Wide CRISPR Screen Reveals Autophagy Disruption as the Convergence Mechanism That Regulates the NRF2 Transcription Factor
Kerins, M. J., Liu, P., Tian, W., Mannheim, W., Zhang, D. D., & Ooi, A. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00037-19 · Cited by 25
MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylases
Lin, A.-P., Qiu, Z., Ethiraj, P., Sasi, B., Jaafar, C., Rakheja, D., & Aguiar, R. C. T. (2022) · Leukemia · doi:10.1038/s41375-021-01489-7 · Cited by 25
TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation
Guo, Q., Cheng, Z., Gonzalez‐Cantu, H., Rotondi, M. L., Huelgas‐Morales, G., Ethiraj, P., Qiu, Z., Lefkowitz, J., Song, W., Landry, B. N., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113070 · Cited by 24
RNA splicing analysis deciphers developmental hierarchies and reveals therapeutic targets in adult glioma
Song, X., Tiek, D. M., Miki, S., Huang, T., Lu, M., Goenka, A., Iglesia, R. P., Yu, X., Wu, R., Walker, M. N., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173789 · Cited by 25
Green Transfection: Cationic Lipid Nanocarrier System Derivatized from Vegetable Fat, Palmstearin Enhances Nucleic Acid Transfections
Dharmalingam, P., Rachamalla, H. K., Lohchania, B., Bandlamudi, B. P., Thangavel, S., Mohankumar, K. M., Banerjee‬‬‬‬‬‬‬‬‬, R., Chaudhuri, A., Voshavar, C., & Marepally, S. K. (2017) · ACS Omega · doi:10.1021/acsomega.7b00935 · Cited by 25
Delivery methods for site-specific nucleases: Achieving the full potential of therapeutic gene editing
Liu, J., & Shui, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.014 · Cited by 24
Three-dimensional ex vivo co-culture models of the leukaemic bone marrow niche for functional drug testing
Dhami, S. P. S., Kappala, S. S., Thompson, A., & Szegezdi, É. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.019 · Cited by 24
Gene correction of HAX1 reversed Kostmann disease phenotype in patient-specific induced pluripotent stem cells
Pittermann, E., Lachmann, N., MacLean, G. A., Emmrich, S., Ackermann, M., Göhring, G., Schlegelberger, B., Welte, K., Schambach, A., Heckl, D., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003798 · Cited by 24
Self-citation
The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency
Sperber, H. S., Raymond, K. A., Bouzidi, M. S., Ma, T., Valdebenito, S., Eugenín, E. A., Roan, N. R., Deeks, S. G., Winning, S., Fandrey, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113285 · Cited by 23
CRISPR/Cas9 Genome Editing Using Gold‐Nanoparticle‐Mediated Laserporation
Bošnjak, B., Permanyer, M., Sethi, M. K., Galla, M., Maetzig, T., Heinemann, D., Willenzon, S., Förster, R., Heisterkamp, A., & Kalies, S. (2018) · Advanced Biosystems · doi:10.1002/adbi.201700184 · Cited by 23
Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR-Cas9 into target cells
Baron, Y., Sens, J., Lange, L., Nassauer, L., Klatt, D., Hoffmann, D., Kleppa, M., Barbosa, P. V., Keisker, M., Steinberg, V., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.12.033 · Cited by 23
RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations
Brabetz, O., Alla, V., Angenendt, L., Schliemann, C., Berdel, W. E., Arteaga, M. F., & Mikesch, J. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.012 · Cited by 22
Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells
Shi, X. E., Kitano, A., Jiang, Y., Luu, V., Hoegenauer, K. A., & Nakada, D. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.04.009 · Cited by 21
microRNA-22 promotes megakaryocyte differentiation through repression of its target, GFI1
Weiss, C. N., & Ito, K. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018023804 · Cited by 22
Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia
Jaiswal, A. K., Truong, H., Tran, T. M., Lin, T. L., Casero, D., Alberti, M. O., & Rao, D. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-92448-w · Cited by 22
CRISPR-Cas9 Technology for the Creation of Biological Avatars Capable of Modeling and Treating Pathologies: From Discovery to the Latest Improvements
Nasrallah, A., Sulpice, E., Kobaisi, F., Gidrol, X., & Rachidi, W. (2022) · Cells · doi:10.3390/cells11223615 · Cited by 26
Suppression of KSHV lytic replication and primary effusion lymphoma by selective RNF5 inhibition
Li, X., Wang, F., Zhang, X., Sun, Q., & Kuang, E. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011103 · Cited by 21
Chromosomal Translocation Formation Is Sufficient to Produce Fusion Circular RNAs Specific to Patient Tumor Cells
Babin, L., Piganeau, M., Renouf, B., Lamribet, K., Thirant, C., Deriano, L., Mercher, T., Giovannangeli, C., & Brunet, E. (2018) · iScience · doi:10.1016/j.isci.2018.06.007 · Cited by 20
RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia
Sharma, G., Tran, T. M., Bansal, I., Beg, M. S., Bhardwaj, R., Bassi, J. S., Tan, Y.-D., Jaiswal, A. K., Tso, C., Jain, A., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02810-1 · Cited by 20
Applications of CRISPR genome editing technology in drug target identification and validation
Lu, Q., Livi, G. P., Modha, S. S., Yusa, K., Macarrón, R., & Dow, D. J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1317244 · Cited by 21
Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background
Yin, M., Chung, Y. J., Lindsley, R. C., Walker, R. L., Zhu, Y. J., Ebert, B. L., Meltzer, P. S., & Aplan, P. D. (2019) · Blood · doi:10.1182/blood.2018864173 · Cited by 20
Self-citation
TAF1-gene editing alters the morphology and function of the cerebellum and cerebral cortex
Janakiraman, U., Yu, J., Moutal, A., Chinnasamy, D., Boinon, L., Batchelor, S. N., Anandhan, A., Khanna, R., & Nelson, M. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104539 · Cited by 18
TraFo-CRISPR: Enhanced Genome Engineering by Transient Foamy Virus Vector-Mediated Delivery of CRISPR/Cas9 Components
Lindel, F., Dodt, C., Weidner, N., Noll, M., Bergemann, F., Behrendt, R., Fischer, S., Dietrich, J., Cartellieri, M., Hamann, M. V., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.10.006 · Cited by 22
Diaphanous-related formin mDia2 regulates beta2 integrins to control hematopoietic stem and progenitor cell engraftment
Mei, Y., Han, X., Liu, Y., Yang, J. C., Sumagin, R., & Ji, P. (2020) · Nature Communications · doi:10.1038/s41467-020-16911-4 · Cited by 20
Application of genome editing technologies to the study and treatment of hematological disease
Pellagatti, A., Dolatshad, H., Yip, B. H., Valletta, S., & Boultwood, J. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.09.005 · Cited by 20
Application of CRISPR-mediated genome engineering in cancer research
Sayin, V. I., & Papagiannakopoulos, T. Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.029 · Cited by 20
Abrogation of Marek’s disease virus replication using CRISPR/Cas9
Hagag, I. T., Wight, D. J., Bartsch, D., Sid, H., Jordan, I., Bertzbach, L. D., Schusser, B., & Kaufer, B. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-67951-1 · Cited by 19
CRISPR-Cas9 Genome Engineering: Trends in Medicine and Health
Zaib, S., Khan, I. A., & Saleem, M. A. (2021) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666210913112030 · Cited by 20
Recent advances in regenerative medicine
Rajpoot, K., Safavi, M., Sreeharsha, N., & Tekade, R. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814455-8.00011-6 · Cited by 18
SETD1A regulates transcriptional pause release of heme biosynthesis genes in leukemia
Hoshii, T., Perlee, S. C., Kikuchi, S., Rahmutulla, B., Fukuyo, M., Masuda, T., Ohtsuki, S., Soga, T., Nabet, B., & Kaneda, A. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111727 · Cited by 18
Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
Pandey, G. K., Landman, N., Neikes, H. K., Hulsman, D., Lieftink, C., Beijersbergen, R. L., Kolluri, K. K., Janes, S. M., Vermeulen, M., Badhai, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100915 · Cited by 18
Lung-specific MCEMP1 functions as an adaptor for KIT to promote SCF-mediated mast cell proliferation
Choi, Y. J., Yoo, J., Jung, K. L., Rice, L., Kim, D.-K., Zlojutro, V., Frimel, M., Madden, E., Choi, U. Y., Foo, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37873-3 · Cited by 19
Modeling Cancer in the CRISPR Era
Ventura, A., & Dow, L. E. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050455 · Cited by 18
CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases
Antony, J. S., Haque, A. K. M. A., Lamsfus‐Calle, A., Daniel-Moreno, A., Mezger, M., & Kormann, M. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.10 · Cited by 20
Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-κB Binding Sites
Chung, C.-H., Allen, A. G., Atkins, A., Sullivan, N. T., Homan, G., Costello, R., Madrid, R., Nonnemacher, M. R., Dampier, W., & Wigdahl, B. L. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.016 · Cited by 19
Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure
Kostyusheva, A., Kostyushev, D. S., Brezgin, S., Volchkova, E. V., & Chulanov, V. (2018) · Genes · doi:10.3390/genes9100483 · Cited by 18
Drug Discovery Oncology in a Mouse: concepts, Models and Limitations
Long, J. E., Jankovic, M., & Maddalo, D. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0019 · Cited by 17
Optimization of CRISPR–Cas system for clinical cancer therapy
Meng, X. L., Wu, T., Lou, Q., Niu, K., Jiang, L., Xiao, Q., Xu, T., & Zhang, L. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10474 · Cited by 18
The CRISPR revolution and its impact on cancer research
Kannan, R., & Ventura, A. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14230 · Cited by 17
Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes
Labenski, V., Suerth, J. D., Barczak, E., Heckl, D., Lévy, C., Bernadin, O., Charpentier, E., Williams, D. A., Fehse, B., Verhoeyen, E., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.019 · Cited by 18
Self-citation
Lentiviral Fluorescent Genetic Barcoding for Multiplex Fate Tracking of Leukemic Cells
Maetzig, T., Rüschmann, J., Milde, L. S., Lai, C. K., von Krosigk, N., & Humphries, R. K. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.05.007 · Cited by 17
The mitochondrial metabolic function of DJ‐1 is modulated by 14‐3‐3β
Weinert, M., Millet, A. M. C., Jonas, E. A., & Alavian, K. N. (2019) · The FASEB Journal · doi:10.1096/fj.201802754r · Cited by 18
多样化CRISPR技术在动物体内基因编辑研究中的应用和进展
马迅, Ma, X., 黄芯渝, 谭晞彦, 崔雍建, 钟礼瞬, 冯波, Wong, A. S.-Y., Tam, H.-Y., Tsui, S. Y.-K., et al. (2018) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2017.012 · Cited by 17
Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression
Rivas, C., Schiff, H. V., Moutal, A., Khanna, R., Kiela, P. R., Dussor, G. O., Price, T. J., Vágner, J., DeFea, K., & Boitano, S. A. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.12.090 · Cited by 17
Deciphering Combinatorial Genetics
Wong, A. S. L., Choi, G. C. G., & Lu, T. K. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-120215-034902 · Cited by 17
Gene surgery
El-Kenawy, A. E.-M., Benarba, B., Neves, A. F., Araújo, T. G., Tan, B. L., & Gouri, A. (2019) · EXCLI journal · doi:10.17179/excli2019-1833 · Cited by 16

Authors: Heckl, D., Kowalczyk, M. S., Yudovich, D., Belizaire, R., Puram, R. V., McConkey, M. E., Thielke, A., Aster, J. C., Regev, A., & Ebert, B. L.
Affiliations: Brigham and Women's Hospital (US)
Broad Institute (US)
Corresponding author: Ebert, Benjamin L
ORCID: Heckl, Dirk
Kowalczyk, Monika S
Yudovich, David
Belizaire, Roger
McConkey, Marie E
Aster, Jon C
Regev, Aviv
Ebert, Benjamin L
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2014-06-22
Volume: 32
Issue: 9
Pages: 941-946
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.2951
PMC: PMC4160386
OpenAlex: W1575193685
Cited by: 555
References: 27
Citations by year: 2026: 14 · 2025: 29 · 2024: 28 · 2023: 58 · 2022: 58 · 2021: 58 · 2020: 61 · 2019: 51 · 2018: 54 · 2017: 61 · 2016: 38 · 2015: 39 · 2014: 5
FWCI: 19.53
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
Funders: National Heart, Lung, and Blood Institute (R01HL082945)
National Human Genome Research Institute (P50HG006193)
National Cancer Institute (P01CA108631, P01CA066996)
National Institute of General Medical Sciences (T32GM007753)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: myeloid neoplasms, acute myeloid leukemia, mouse tumor model, CRISPR/Cas9 genome editing, lentiviral delivery, hematopoietic stem cells, clonal outgrowth, driver mutations, epigenetic regulators, transcription factors, cytokine signaling, cooperating mutations
MeSH terms: Animals, Disease Models, Animal, Bone Marrow Neoplasms, Mice, Clustered Regularly Interspaced Short Palindromic Repeats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks